C-reactive protein's role in monitoring severe pneumonia
Author Information
Author(s): Coelho Luís, Póvoa Pedro, Almeida Eduardo, Fernandes Antero, Mealha Rui, Moreira Pedro, Sabino Henrique
Primary Institution: Unidade de Cuidados Intensivos, Hospital Garcia de Orta, Almada, Portugal
Hypothesis
Daily monitoring of plasma CRP can recognize patients with bad outcome and patients with good outcome early in the course of antibiotic treatment.
Conclusion
Daily C-reactive protein measurement after antibiotic prescription is useful in identifying severe community-acquired pneumonia patients with poor outcomes as early as day 3.
Supporting Evidence
- By day 3, a C-reactive protein level 0.5 times the initial level was a marker of poor outcome.
- Patients with a fast response pattern had a survival rate of 96%.
- Patients with a slow response pattern had a survival rate of 74%.
- Patients with nonresponse and biphasic response patterns had mortality rates of 100% and 33%, respectively.
Takeaway
Doctors can use a blood test for C-reactive protein to see how well patients with severe pneumonia are responding to treatment, helping them know who is getting better and who is not.
Methodology
A cohort of 53 patients with severe community-acquired pneumonia was studied, monitoring C-reactive protein levels, body temperature, and white cell count daily after antibiotic prescription.
Limitations
The study is a single-centre, observational cohort study, which may limit the generalizability of the findings.
Participant Demographics
Patients aged ≥18 years admitted for severe community-acquired pneumonia.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% confidence interval = 0.61–0.87
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website